IDH1 and neoplasm: From DPI 9 of palpable tumor, mice bearing CT26 tumor and mice bearing CT26 tumor with IDH1 mutation were intravenously administered with 50 mg/kg ivosidenib or PBS as NTC control every day for the following experimental period32.